AbbVie (NYSE: ABBV) boasts a portfolio of drugs across immunology, neuroscience, aesthetics, oncology, and eye care. Yet investors' focus lately has been on the fate of one particular product: the immunology drug Humira. That's because it's set to face competition in the U.S. as of this month.

Why is this such a problem? It's because Humira has become a megablockbuster. In 2021, the product brought in more than $20 billion in sales. And over its two decades on the market, Humira has generated almost $200 billion in sales, according to BioPharma Dive.

But I think investors shouldn't worry too much about the upcoming loss of exclusivity. Here's why.

Continue reading

Source Fool.com